Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

This study is currently recruiting participants.

Verified by Huazhong University of Science and Technology, August 2006

First Received: August 4, 2006 No Changes Posted

Sponsor:	Huazhong University of Science and Technology
Information provided by:	Huazhong University of Science and Technology
ClinicalTrials.gov Identifier:	NCT00360763

Purpose

The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.

Condition	Intervention	Phase
Hypertension	Drug: candesartan cilexetil	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Resource links provided by NLM:

Genetics Home Reference related topics: ataxia-telangiectasia

MedlinePlus related topics: Ataxia Telangiectasia High Blood Pressure

Drug Information available for: CV 11974 Candesartan cilexetil

U.S. FDA Resources

Further study details as provided by Huazhong University of Science and Technology:

Estimated Enrollment:	600
Estimated Study Completion Date:	December 2006

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Hypertension (2 grade)

Exclusion Criteria:

Secondary hypertension
Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
Pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00360763

Locations

China, Hubei
Department of Cardiology, Wuhan Union Hospital	Recruiting
Wuhan, Hubei, China, 430022
Contact: Yu-Hua Liao, Doctor 00862785726376 yumiaowei@vip.sina.com

Sponsors and Collaborators

Huazhong University of Science and Technology

Investigators

Study Director:

Yu-Hua Liao

Union Hospital, Tongji Medical College

More Information

Publications:

Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002 Jul;25(4):641-6.

Study ID Numbers:	UH-01
Study First Received:	August 4, 2006
Last Updated:	August 4, 2006
ClinicalTrials.gov Identifier:	NCT00360763 History of Changes
Health Authority:	China: State Food and Drug Administration

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Candesartan cilexetil
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Candesartan
Vascular Diseases

Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010